Literature DB >> 11427223

The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria.

C J Deighan1, M J Caslake, M McConnell, J M Boulton-Jones, C J Packard.   

Abstract

The dyslipidaemia in nephrotic-range proteinuria is believed to contribute to the increased atherogenesis associated with the condition. Excess small dense low density lipoprotein (LDLIII) contributes to this risk. Lipoprotein remnants (RLP) may also be implicated but have not been studied in this population. We measured the plasma concentration of low density lipoprotein (LDL) subfractions (by density gradient ultracentrifugation), RLP (by immunoaffinity gel), very low density lipoprotein (VLDL) subfractions, post heparin lipases and cholesteryl ester transfer protein (CETP) activity in 27 patients with glomerular disease and albuminuria >2.0g. These were compared with 27 age and sex matched controls. Proteinuric patients had increased LDLIII concentration (patients 182 (84:267) vs. controls 31 (27:62); P<0.0001) with reduced lighter LDLI (36 (24:43) vs 69 (46:101); P<0.0005) and LDLII (124 (79:220) vs 178 (129:236); P<0.04, all mg/dl, median+interquartile range). RLP-cholesterol (RLP-C) and triglyceride (RLP-TG) were increased in proteinuric patients (RLP-C 18.9 (11.0:26.9) vs 7.7 (6.0:8.8); P<0.0001, RLP-TG 35.8 (11.8:54.7) vs. 7.2 (4.3:10.0); P<0.0001, all mg/dl). Increased LDLIII and RLP were independent of renal function. VLDL(1) and VLDL(2) concentrations were increased by 258 and 260% (both P<0.0001). CETP activity was increased by 46% (P<0.005). Lipoprotein and hepatic lipase activities did not differ from control values. LDLIII concentration (r(2)=45.7%, P<0.001), RLP-C (r(2)=85.2%, P<0.001) and RLP-TG (r(2)=87.5%, P<0.001) all correlated positively with plasma triglyceride. Moreover, increased LDLIII was associated with both RLP-C (r(2)=31.3%, P<0.002) and RLP-TG (r(2)=33.6%, P<0.002). Excess LDLIII and RLP are present in nephrotic-range proteinuria and add to the spectrum of cardiovascular risk factors present in proteinuric patients. Increases in LDLIII and RLP are closely related to plasma triglyceride. The association between excess RLP and LDLIII suggests that RLP contribute to the increased atherogenicity attributed to the atherogenic lipoprotein phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427223     DOI: 10.1016/s0021-9150(00)00710-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Changes in LDL and HDL subclasses in normal pregnancy and associations with birth weight, birth length and head circumference.

Authors:  Aleksandra Zeljkovic; Jelena Vekic; Slavica Spasic; Zorana Jelic-Ivanovic; Vesna Spasojevic-Kalimanovska; Tamara Gojkovic; Daniela Ardalic; Vesna Mandic-Markovic; Nikola Cerovic; Zeljko Mikovic
Journal:  Matern Child Health J       Date:  2013-04

Review 2.  Postprandial lipoprotein metabolism: VLDL vs chylomicrons.

Authors:  Katsuyuki Nakajima; Takamitsu Nakano; Yoshiharu Tokita; Takeaki Nagamine; Akihiro Inazu; Junji Kobayashi; Hiroshi Mabuchi; Kimber L Stanhope; Peter J Havel; Mitsuyo Okazaki; Masumi Ai; Akira Tanaka
Journal:  Clin Chim Acta       Date:  2011-04-19       Impact factor: 3.786

Review 3.  Dyslipidemia in patients with chronic kidney disease.

Authors:  Matthew R Hager; Archana D Narla; Lisa R Tannock
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

4.  Lipoproteins and cholesterol homeostasis in paediatric nephrotic syndrome patients.

Authors:  Yonas Mulat Simachew; Tamara Antonić; Tamara Gojković; Sandra Vladimirov; Marija Mihajlović; Sanja Vujčić; Gordana Miloševski-Lomić; Jelena Vekić; Aleksandra Zeljković; Vesna Spasojević-Kalimanovska; Amira Peco-Antić; Dušan Paripović; Aleksandra Stefanović
Journal:  Biochem Med (Zagreb)       Date:  2022-06-15       Impact factor: 2.515

5.  Association of remnant cholesterol with chronic kidney disease in middle-aged and elderly Chinese: a population-based study.

Authors:  Pijun Yan; Yong Xu; Ying Miao; Xue Bai; Yuru Wu; Qian Tang; Zhihong Zhang; Jiong Yang; Qin Wan
Journal:  Acta Diabetol       Date:  2021-06-28       Impact factor: 4.280

Review 6.  Cholesterol Metabolism in CKD.

Authors:  Allison B Reiss; Iryna Voloshyna; Joshua De Leon; Nobuyuki Miyawaki; Joseph Mattana
Journal:  Am J Kidney Dis       Date:  2015-09-01       Impact factor: 8.860

7.  Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.

Authors:  Archna Bajaj; Dawei Xie; Esteban Cedillo-Couvert; Jeanne Charleston; Jing Chen; Rajat Deo; Harold I Feldman; Alan S Go; Jiang He; Edward Horwitz; Radhakrishna Kallem; Mahboob Rahman; Matthew R Weir; Amanda H Anderson; Daniel J Rader
Journal:  Am J Kidney Dis       Date:  2019-01-25       Impact factor: 8.860

8.  Dyslipidemia associated with chronic kidney disease.

Authors:  Vasilis Tsimihodimos; Zoi Mitrogianni; Moses Elisaf
Journal:  Open Cardiovasc Med J       Date:  2011-02-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.